The collaboration builds on a successful pilot between the two companies and will leverage Genetic Leap ’ s RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas . The central role of RNA in orchestrating essential biological processes holds significant potential to address critical diseases that traditional drugs have not been able to target effectively . Historically , drugging RNA has presented tremendous challenges . Genetic Leap ’ s proprietary AI platform is revolutionising the approach to drugging RNA .

“ We are thrilled to collaborate with Lilly and deeply share their strong commitment to developing RNA medicines ,” said Dr Bertrand Adanve ,

CEO and Founder of Genetic Leap . “ Our primary goal in building the Genetic Leap AI platform is to accelerate the development of lifesaving medicines for patients , and this collaboration with Lilly ’ s talented and savvy R & D team takes us significantly closer to that goal .”

Under the terms of the agreement , Genetic Leap will receive from Lilly up to US $ 409 million in upfront , development , clinical , regulatory and commercial milestone payments , in addition to tiered royalties . �

52 www . intelligenthealth . tech